Lilly’s Kisunla Demonstrates Growing Benefit in Treating Early Alzheimer’s Disease

Lilly’s Kisunla Demonstrates Growing Benefit in Treating Early Alzheimer’s Disease

Findings from a Phase III study highlight the demonstrated action of donanemab-azbt (brand name Kisunla) in slowing the decline of patients exhibiting early symptomatic Alzheimer’s disease.

Lilly’s Kisunla (donanemab-azbt) showed growing benefit over three years in early symptomatic Alzheimer’s disease

Eli Lilly and Company (NYSE: LLY) announced results from the long-term extension (LTE) of the Phase 3 TRAILBLAZER-ALZ 2 study showing that participants treated with Kisunla (donanemab-azbt) demonstrated slowing of decline, a benefit that continued to grow over three years compared to an untreated external cohort from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Participants in the study who started treatment later still saw benefit. H…